{
    "clinical_study": {
        "@rank": "148250", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of UCN-01 in treating patients who have\n      unresectable stage III or stage IV kidney cancer."
        }, 
        "brief_title": "UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer", 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy of UCN-01, in terms of time to objective progression, in\n           patients with stage IV or unresectable stage III renal cell carcinoma.\n\n        -  Determine the objective response rate in patients treated with this drug.\n\n      OUTLINE: Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in\n      the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 21-61 patients will be accrued for this study within 15\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed stage IV or unresectable stage III renal\n             cell carcinoma\n\n               -  Metastatic disease must be amenable to biopsy or appropriate for nephrectomy\n                  before study therapy\n\n          -  At least 1 unidimensionally measurable lesion\n\n               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n\n          -  No known prior or concurrent CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  AST/ALT no greater than 2.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine normal OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No history of clinically significant coronary artery disease\n\n          -  No symptomatic cardiac dysfunction\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Pulmonary:\n\n          -  No symptomatic pulmonary dysfunction\n\n        Other:\n\n          -  No prior allergic reactions to compounds of similar chemical or biological\n             composition to UCN-01\n\n          -  No other uncontrolled concurrent illness\n\n          -  No active or ongoing infection\n\n          -  No known immune deficiency\n\n          -  No psychiatric illness or social situation that would preclude study compliance\n\n          -  No insulin-dependent diabetes mellitus\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 6 months after study\n             participation\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  No prior mediastinal radiation\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior nephrectomy\n\n        Other:\n\n          -  No more than 2 prior systemic therapies for metastatic renal cell carcinoma\n\n          -  No other concurrent investigational agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030888", 
            "org_study_id": "CDR0000069208", 
            "secondary_id": [
                "UCSF-NCI-5522", 
                "NCI-5522"
            ]
        }, 
        "intervention": {
            "intervention_name": "7-hydroxystaurosporine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "7-hydroxystaurosporine", 
                "Staurosporine"
            ]
        }, 
        "keyword": [
            "stage III renal cell cancer", 
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCSF-NCI-5522"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "UCSF Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94121"
                    }, 
                    "name": "Veterans Affairs Medical Center - San Francisco"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase 2 Study Of UCN-01 In Advanced Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Brian I. Rini, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030888"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2002", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2003"
    }, 
    "geocoordinates": {
        "UCSF Comprehensive Cancer Center": "37.775 -122.419", 
        "Veterans Affairs Medical Center - San Francisco": "37.775 -122.419"
    }
}